- Home
- CHRS vs SRFM Comparison
CHRS vs SRFM Comparison
Compare CHRS & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SRFM
- Stock Information
- Founded
- CHRS 2010
- SRFM 2011
- Country
- CHRS United States
- SRFM United States
- Employees
- CHRS N/A
- SRFM N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SRFM Transportation Services
- Sector
- CHRS Health Care
- SRFM Consumer Discretionary
- Exchange
- CHRS Nasdaq
- SRFM Nasdaq
- Market Cap
- CHRS 194.1M
- SRFM 191.9M
- IPO Year
- CHRS 2014
- SRFM 2023
- Fundamental
- Price
- CHRS $1.69
- SRFM $4.94
- Analyst Decision
- CHRS Strong Buy
- SRFM Buy
- Analyst Count
- CHRS 4
- SRFM 4
- Target Price
- CHRS $4.51
- SRFM $5.75
- AVG Volume (30 Days)
- CHRS 1.4M
- SRFM 3.1M
- Earning Date
- CHRS 11-05-2025
- SRFM 11-13-2025
- Dividend Yield
- CHRS N/A
- SRFM N/A
- EPS Growth
- CHRS N/A
- SRFM N/A
- EPS
- CHRS 1.55
- SRFM N/A
- Revenue
- CHRS $272,209,000.00
- SRFM $107,372,000.00
- Revenue This Year
- CHRS N/A
- SRFM N/A
- Revenue Next Year
- CHRS $109.48
- SRFM $18.06
- P/E Ratio
- CHRS $3.27
- SRFM N/A
- Revenue Growth
- CHRS 52.33
- SRFM N/A
- 52 Week Low
- CHRS $0.66
- SRFM $1.50
- 52 Week High
- CHRS $2.43
- SRFM $9.91
- Technical
- Relative Strength Index (RSI)
- CHRS 62.59
- SRFM 58.25
- Support Level
- CHRS $1.63
- SRFM $4.82
- Resistance Level
- CHRS $1.89
- SRFM $5.32
- Average True Range (ATR)
- CHRS 0.12
- SRFM 0.42
- MACD
- CHRS 0.00
- SRFM 0.09
- Stochastic Oscillator
- CHRS 64.42
- SRFM 46.69
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.